Richard A. Kayne - Oct 31, 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc. (EIGR)

Role
10%+ Owner
Signature
/s/ Richard A. Kayne
Stock symbol
EIGR
Transactions as of
Oct 31, 2023
Transactions value $
$72,815
Form type
4
Date filed
11/2/2023, 09:21 PM
Previous filing
Oct 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EIGR Common Stock Purchase $3.15K +12K +0.24% $0.26 5.11M Oct 31, 2023 See footnote. F1, F3
transaction EIGR Common Stock Purchase $3.23K +12.3K +0.24% $0.26 5.12M Oct 31, 2023 See footnote. F1, F3
transaction EIGR Common Stock Purchase $31.5K +131K +2.55% $0.24 5.25M Oct 31, 2023 See footnote. F2, F3
transaction EIGR Common Stock Purchase $28K +100K +1.9% $0.28 5.35M Nov 1, 2023 See footnote. F2, F3
transaction EIGR Common Stock Purchase $6.97K +23.4K +0.44% $0.30 5.38M Nov 2, 2023 See footnote. F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Mr. Kayne shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Mr. Kayne and Propel General Partner act as the general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds acquired the referenced shares of Common Stock.
F2 Mr. Kayne is the trustee and beneficiary of the Richard Kayne and Suzanne Kayne Living Trust dtd 01/14/1999, a California trust (the "Family Trust"), and the Family Trust acquired the referenced shares of Common Stock.
F3 Mr. Kayne expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest.